摘要
目的探讨脾肾阳虚型慢性心力衰竭(chronic heart failure,CHF)患者与非脾肾阳虚型慢性心力衰竭患者血浆中氨基末端B型利钠肽前体(NT-proBNP)和同型半胱氨酸(HCY)的水平及临床意义。方法将慢性心力衰竭患者进行中医辨证分型,选取脾肾阳虚型患者(A组)与非脾肾阳虚型患者(B组),各60例。检测两组患者血浆NT-proBNP、HCY水平,并对两组数值进行比较。结果 A组患者NT-proBNP和HCY水平明显高于B组,差异有高度统计学意义(P<0.01)。随着心力衰竭分级增加,患者NT-proBNP、HCY水平也逐渐增加,差异有高度统计学意义(P<0.01)。结论 NT-proBNP、HCY可以作为评价脾肾阳虚型心力衰竭患者心衰严重程度的客观性指标,并具有临床可操作性。
Objective To investigate the clinical significance of plasma NT-proBNP and HCY in chronic heart failure patients with spleen kidney yang deficiency type and non-spleen and kidney yang deficiency type. Methods The patients with chronic heart failure were divided into spleen kidney yang deficiency type（group A） and non-spleen and kidney yang deficiency type（group B） by syndrome differentiation of traditional Chinese medicine, and each group had60 patients. The levels of plasma NT-proBNP, HCY in the two groups were tested and compared. Results The levels of plasma NT-proBNP, HCY in group A were significantly higher than those in group B, the differences were statistically significant（P〈0.01）. With the increase of cardiac functional grading, the levels of plasma NT-proBNP, HCY increased, the differences were statistically significant（P〈0.01）. Conclusion NT-proBNP, HCY can be used as objectivity index for seriousness evaluation in chronic heart failure patients with spleen kidney yang deficiency type, and have clinical feasibility.
出处
《中国医药导报》
CAS
2014年第19期44-46,55,共4页
China Medical Herald
基金
山东省青岛市卫生局中医科研计划项目(编号2011-zyy019)
